Description of the medicine: Calcitrine (Calcitrinum)

Calcitrinum (Calcitrinum).

The drug, prepared from calcitonin, obtained from the thyroid glands of pigs. It is intended for parenteral use.

Issued in the form of a sterile lyophilized white powder. The aqueous solutions of the preparation are clear, colorless; PH 3, 0 - 6, O. The activity is determined by biological means and expressed in units of action (ED). In 1 mg of the drug contains not less than 60 units.

Indications for use are the same as for calcitonin.

Calcitrine is administered intramuscularly or subcutaneously. The drug is dissolved in sterile water for injection immediately before use. When starting treatment, the calcium content in the blood is determined, as well as the skin test is carried out - 1 ED of calcitrine is injected intradermally in 0.1 ml of the solvent. Patients with severe skin reaction to calcitrine (intensive erythema, swelling) are not treated.

The drug is administered once a day daily for a month with a break every 7th day or every other day for 2 to 3 months. Treatment is started in the hospital and is continued on an outpatient basis.

For athletes with pathological zonal bone reshaping, patients with delayed fracture fusion, in mild cases of osteoporosis, with non-endocrine diseases requiring long-term use of glucocorticoids, the drug is prescribed 1 unit per day.

With systemic lesions of the skeleton of moderate severity, as well as traumatic and other osteomyelitis, the drug is prescribed 2 to 3 units per day, in the case of severe forms of systemic and focal lesions of the skeleton, 5 units per day.

Repeated injection is carried out no earlier than 2 months, with diseases of mild and moderate severity - usually after 6 to 12 months.

Along with calcitrine, it is recommended to prescribe calcium preparations (glycerophosphate or calcium gluconate 4-6 g per day).

During treatment with calcitrine, allergic reactions at the injection site, blood flushing to the face, increased blood pressure are possible. In these cases, they take a break for 2 to 3 days. The appearance of repeated expressed reactions requires the withdrawal of the drug.

The administration of calcitrine in elevated doses (more than 5 units per injection) may be accompanied by nausea, sometimes vomiting.

If an overdose or hypersensitivity of the patient to the drug develops signs of hypocalcemia (paresthesia, muscle twitching), then parenteral calcium gluconate is introduced.

Contraindicated in hypocalcemia, pregnancy and lactation.

Form release: sterile lyophilized powder of 10 and 15 units in hermetically sealed vials.

Storage: List B. In dry, the dark place at a temperature of no more than +20 C. The solution of the drug is stored at a temperature of + 4 C not more than 5 days.

There are data on the use of calcitrine in the form of inhalations (1 - 2 units in 1 to 2 ml of distilled water, for a course of 8 to 10 inhalations) with obstructive bronchitis (in complex therapy).